Supernus Pharmaceuticals Inc (SUPN) Prix

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. The company is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.